2076975 2077203
최종편집 2024-03-29 00:50 (금)
Roche Avastin triple combo receive expanded reimbursement for metastatic colorectal cancer
상태바
Roche Avastin triple combo receive expanded reimbursement for metastatic colorectal cancer
  • Hanki Lee
  • 승인 2020.02.26 14:18
  • 댓글 0
이 기사를 공유합니다

HIRA, established revision in reimbursement criteria...Go into effect on March 1
‘Irinotecan + Low-Dose Capecitabine + Bevacizumab’ Combination will be covered by health insurance

Health insurance coverage for Roche’s anti-cancer drug Avastin(Bevacizumab) is expected to expand.

Avastin is indicated in Korea for the treatment of ▲ metastatic colorectal cancer ▲ metastatic breast cancer ▲ non–small cell lung cancer ▲ advanced or metastatic renal cell carcinoma ▲ glioblastoma ▲ epithelial ovarian, fallopian tube, or primary peritoneal cancer ▲ cervical cancer.

In particular, Avastin is approved for use in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy in second-line metastatic colorectal cancer.

Under these circumstances, the Health Insurance Review and Assessment Service(HIRA) prepared a revision of ‘Details on the application criteria and methods of medical care benefits for drugs prescribed and administered to cancer patients’ and recently preannounced.

The revision set up a basis for reimbursement from health insurance for the use in combination with irinotecan + low-dose capecitabine(mCAPIRI) + bevacizumab in second-line metastatic colorectal cancer.

Regarding this, the HIRA said the triple combination regimens of ‘irinotecan + low-dose capecitabine + bevacizumab’ have not been mentioned in textbooks and NCCN guidelines, but the ESMO(European Society for Medical Oncology) 2018 guidelines states that it is currently under study.

In addition, “in the non-inferiority, phase III clinical trial(AXEPT), which compares the triple combination regimens to FOLFIRI ± bevacizumab, that is currently reimbursed by insurance, the median overall survival(mOS) was 16.8 months and 15.4 months respectively, demonstrating non-inferiority.” the HIRA said.

Also, the HIRA explained the background of the revision that deciding to grant medical care benefits for metastatic colorectal cancer, considering the advantages of improving convenience of ambulatory care compared to the currently reimbursed treatment, as well as possibility of providing patients with a choice of treatment.

The HIRA will collecting opinions on the revision by 21st(Friday) and will implement on the 1st of next month if there is no disagreement.

 

 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.